References

  1. Frasch CE, Preziosi M-P, LaForce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVacTM. Human Vaccines and Immunotherapy. 2012;8(6): 715–24.

  2. Unicef. Joint press release: 100 millionth person receives lifesaving meningitis vaccine. http://www.unicef.org/media/media_66534.html. Accessed August 07 2014.

  3. US Centers for Disease Control and Prevention: Serogroup. A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011. MMWR Morbidity and Mortality Weekly Report. 2012;61(50):1022–4. PubMed | Google Scholar

  4. Caini S, Beck NS, Yacouba H, Maiga I, Chaibou I, Hinsa I, et al. Estimating coverage of the MenAfriVacTM conjugate vaccine against meningococcal serogroup A in Niger, September 2010 - January 2012. Vaccine. 2013;31(12):1597-1603. PubMed | Google Scholar

  5. Kristiansen PA, Diomandé F, Ba AK, Sanou I, Ouédraogo AS, Ouédraogo R, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clinical Infectious Disease. 2013;56(3):354–63. PubMed | Google Scholar

  6. Novak RT, Kambou JL, Diomandé FV, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infectious Diseases. 2012;12(10):757–64. PubMed | Google Scholar

  7. Serum Institute of India. Meningococcal A Conjugate Vaccine Lyophilized MenAfriVacTM. http://www.seruminstitute.com/content/products/product_menafrivac.html. Accessed August 07 2014.

  8. Kshirsagar N, Mur N, Thatte U, Gogtay N, Viviani S, Preziosi MP, et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine. 2007;25(Suppl 1):A101–7. PubMed | Google Scholar

  9. Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, Carlone G, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. New England Journal of Medicine. 2011;364(24):2293–304. PubMed | Google Scholar

  10. World Health Organization. Meningococcal A conjugate 10 dose presentation. http://www.who.int/immunization_standards/vaccine_quality/PQ_197_MenAconjugate_10dose_SII/en/index.html. Accessed August 07 2014.

  11. World Health Organization. Revolutionary meningitis vaccine breaks another barrier; first to gain approval to travel outside cold chain 2012. http://www.who.int/immunization/newsroom/menafrivac_20121114/en/index.html. Accessed August 07 2014.

  12. WHO. Global Advisory Committee on Vaccine Safety,3-4 December 2009. Weekly Epidemiological Record. 2010;85(5):29–33. PubMed | Google Scholar

  13. WHO. Meeting of the Global Advisory Committee on Vaccine Safety, June 2011. Weekly Epidemiological Record. 2011;86(30):321–4. PubMed | Google Scholar

  14. Chaibou MS, Bako H, Salisou L, Yameogo TM, Sambo M, Kim SH, et al. Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010. Vaccine. 2012;30(35):5229–34. PubMed | Google Scholar

  15. Ouandaogo CR, Yaméogo TM, Diomandé FV, Wawadogo C, Ouedraogo B, Ouedraogo-Traore R, et al. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010. Vaccine. 2012;30(Suppl 2):B46–B51. PubMed | Google Scholar

  16. US Centers for Disease Control and Prevention. Distinguishing public health research and public health nonresearch. Science administration document CDC-SA-2010-02, 2010. http://www.cdc.gov/od/science/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf. Accessed August 07 2014.

  17. Hirve S, Bavdekar A, Pandit A, Juvekar S, Patil M, Preziosi MP, et al. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial. Vaccine. 2012;30(50):6456-60. PubMed | Google Scholar